SEARCH:   Advanced

Blood, 1 March 2006, Vol. 107, No. 5, pp. 1785-1790. Prepublished online as a Blood First Edition Paper on November 15, 2005; DOI 10.1182/blood-2004-09-3501. This Article Full Text (PDF) All Versions of this Article: 2004-09-3501v1 107/5/1785    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tsoukas, C. Articles by Melian, A. Search for Related Content PubMed PubMed Citation Articles by Tsoukas, C. Articles by Melian, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 9, 2004 Accepted October 3, 2005 Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy Christos Tsoukas*, M E Eyster, Sumiko Shingo, Saurabh Mukhopadhyay, Karen M Giallella, Sean P Curtis, Alise S Reicin, and Agustin Melian McGill Univesity Health Centre, Montreal, Quebec, Canada Penn State Hershey Medical Center, Hershey, PA, USA Merck Research Laboratories, Rahway, NJ, USA * Corresponding author; email: chris.tsoukas{at}muhc.mcgill.ca. This two-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy. In Part-I (6 weeks), 102 hemophilic arthropathy patients ( 12 years old) were randomized to etoricoxib 90mg once-daily or placebo (1:1 ratio). In Part-II (6 months), 51 patients taking placebo in Part-I were randomized to receive etoricoxib 90mg or rofecoxib 25mg* once-daily; etoricoxib patients in Part-I continued the same treatment. Efficacy endpoints included Patient Assessment of Arthropathy Pain, Patient Global Assessment of Arthropathy Disease Status, and Investigator Global Assessment of Arthropathy Disease Status. Safety was evaluated at each study visit. Etoricoxib provided significant improvement in all endpoints versus placebo (p< 0.001). Fewer etoricoxib patients discontinued due to a lack of efficacy versus placebo (p=0.048). During Part-II, efficacy was maintained; etoricoxib and rofecoxib demonstrated similar results. The most common adverse experiences were upper respiratory infection and headache. The incidence of joint bleeding during Part-I was similar between etoricoxib (66.7%) and placebo (72.6%) and during Part-II between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy, and was generally safe and well tolerated. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Chilet-Rosell, M. T. Ruiz-Cantero, and J. F. Horga Women's health and gender-based clinical trials on etoricoxib: methodological gender bias J. Public Health Med., September 1, 2009; 31(3): 434 - 445. [Abstract] [Full Text] [PDF] J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020